34 results about "Protein M" patented technology

The invention provides a fusion protein for a novel coronavirus variant strain Delta, a nasal spray vaccine as well as a preparation method and application thereof, and belongs to the technical field of virus vaccines. The fusion protein for the novel coronavirus variant strain Delta is formed by fusing spike protein S, transmembrane protein M and nucleocapsid protein N; and coding genes of the protein S, the protein M and the protein N are sequentially shown as SEQ ID NO: 1-3. The nasal spray vaccine prepared by mixing the fusion protein and an adjuvant has good immunogenicity, safety and biological activity, and can induce an organism to generate an effective antibody, so that the growth of the novel coronavirus variant strain Delta is inhibited, and the Delta infection can be effectively prevented; by adopting the form of the nasal spray vaccine, injection is not needed, the operation is simple and convenient, and adverse reactions after use of an injection vaccine are avoided; and the preparation method of the vaccine is simple, and the vaccine is easy to purify and high in safety, and can be quickly applied to clinical tests.

The present invention specifically relates to a method for protein affinity purification of IgY, which comprises the following steps: 1. gene cloning of protein M; 2. constructing an expression vector, performing soluble expression of protein M through the expression vector, and purifying soluble protein M; 3. The soluble protein M was coupled with NHS-activated Sepharose 4FF to make an affinity purification medium; 4. The primary product of the IgY antibody was affinity purified through a protein M Sepharose column to obtain high-purity IgY, and the primary IgY antibody The product is a mixture of egg yolk liquid and distilled water of equal mass; 5. Dialyze the IgY antibody solution obtained after purification in PBS solution at 4°C overnight, and the pH of the PBS solution is 7.0-7.4; 6. Collect the liquid in the dialysis bag to obtain high purity IgY antibody. The invention has the following beneficial effects: 1. The process is simple; 2. The IgY purification efficiency is as high as 95%; 3. It is more environmentally friendly, green and healthy.

The invention relates to the technical field of animal virology, epizootiology and genetic engineering, in particular to a synthesis method and application of an mMEP of a PRRSV (Porcine Reproductive and Respiratory Syndrome Virus) with high pathogenicity. The synthesis method is characterized in that the T-cell epitopes of the GP3, GP4, GP5, protein M and protein N of a PRRSVWUH3 strain are connected with the epitope of a modified GP5B cell through linkers; according to mammal codon preference, codons are modified to synthesize the mMEP artificially. The nucleotide sequence of the mMEP is shown in SEQ ID NO:1; the protein sequence of the mMEP is shown in SEQ ID NO:2. The synthetic mMEP is contained in an eukaryotic expression plasmid pcDNA3.1-mMEP. Escherichia coli DH5(Alpha) / pcDNA3.1-mMEP containing the eukaryotic expression plasmid pcDNA3.1-mMEP are preserved in China Center for Type Culture Collection (CCTCC), and the preservation number of the escherichia coli DH5(Alpha) / pcDNA3.1-mMEP is CCTCC NO: M 2012171. The invention further discloses application of the mMEP in preparing an PRRS DNA vaccine.

The invention belongs to the field of biotechnology, and in particular relates to an oncolytic virus vaccine and a drug for treating tumors in combination with immune cells. The present invention provides a brand-new attenuated strain of oncolytic virus by performing site-directed mutation on the matrix protein M of the VSV wild-type virus, and its matrix protein M gene sequence is shown in SEQ ID NO 3. The attenuated strain can be used alone as a drug to treat tumors, and its safety and cure rate are superior to wild-type virus and other known attenuated strains. Based on the attenuated strain of oncolytic virus, the present invention also provides a vaccine applicable to tumor treatment by inserting NY-ESO-1 into the attenuated strain. The vaccine has a high cure rate and high biological safety. On the basis of the vaccine, the present invention also uses the vaccine in combination with TCR-T cells to provide a drug that can efficiently treat multiple types of tumors; on a mouse lung cancer model, the cure rate can reach 95%.

The present invention is concerned with a method of identifying microbial strains (e.g. from a cell culture), the method comprising; i) a lipid extraction step, comprising extraction of phospholipids from the microbe, suitably with an extraction composition comprising more than 50 vol % MeOH; ii) a sample preparation step, comprising preparation of a MALDI sample incorporating the extracted lipids; iii) a data gathering step, comprising performing MALDI-based mass spectrometry on the MALDI sample, and iv) a microbe identification step, comprising analysis of the mass spectrometry data to characterise or identify the microbial strain. Suitably the method also includes extracting proteins from the microbes and analysing the extracted proteins using MALDI-based mass spectrometry so as to obtain not only lipid m / z data but also protein m / z data.

The present invention relates to methods and compositions for binding antibodies. The methods may be used to isolate antibodies, treat conditions associated with excess antibodies, acute block antibodies to prevent autoimmune or inflammatory responses, and inhibit neutralizing antibodies. In an embodiment, the present invention relates to a method of inhibiting a neutralizing antibody against a heterologous agent when the heterologous agent is administered to a subject, comprising administering to the subject an effective amount of Mycoplasma Protein M, or a functional fragment or derivative thereof, thereby inhibiting neutralization of the heterologous agent. The invention also relates to a modified Mycoplasma protein M or a functional fragment thereof having increased thermal stability relative to the wild-type protein M and its use in the method of the invention.

The invention discloses a traditional Chinese medicine composition for improving immunity and antioxidant capacity of laying ducks. The traditional Chinese medicine composition for improving the immunity and antioxidant capacity of laying ducks of the present invention is based on the physiological characteristics of laying ducks, and fully considers the principle of Chinese medicine compatibility of eighteen anti and nineteen fears. It is short, synergistic with each other, and adds to each other. It has been proved by experiments that this Chinese medicine composition can significantly improve the serum immunoglobulin G (IgG), immunoglobulin A (IgA), and Protein M (IgM), serum total protein and serum albumin content can improve the immunity of laying ducks, and can enhance the antioxidant performance of laying ducks. The traditional Chinese medicine composition of the invention has wide sources of raw materials, low price, wide range of functions, high safety and remarkable benefits, so it can play a greater role in the laying and duck breeding industry.

The invention relates to avian infectious bronchitis virus (IBV) resistant peptide nucleic acids (PNAs). The PNAs are characterized in that two antisense nucleic acid sequences with strong specificity are designed aiming at the highly conserved domains of genes of proteins M and N of IBV and are specifically combined with target genes corresponding to the two key genes of IBV, namely the proteins M and N; and the proteins M and N are distributed in different domains of the IBV genome, so that the stability and membrane permeability of antisense nucleic acids are improved. The sequences and the target genes reversely complement each other; according to the base complementary principle, the antisense nucleic acid sequences are specifically combined with the target genes corresponding to the IBV (proteins M and N) to induce the molecules, such as ribozyme, to degrade the target genes to block transcription and expression of the target genes and inhibit replication and assembly of the IBV in hosts to achieve the aim of preventing and controlling IB.

The present invention relates to the use of Yersinia outer protein M (YopM)in the prevention and / or treatment of psoriasis by cutaneous, intradermalor subcutaneous administration. In particular, the present invention relates to the use of YopM in the treatment of plaque psoriasis, guttate psoriasis, inverse psoriasis, pustular psoriasis, erythrodermic psoriasis, arthritis psoriasis.

A porcine reproductive and respiratory syndrome virus ELISA antibody detection kit, the kit includes: a protein mixed-encapsulated enzyme label plate, a batch pretreatment device for serum samples, a sample diluent, an enzyme-labeled conjugate, a substrate color developer, and a stop solution , Porcine Reproductive and Respiratory Syndrome positive serum and Porcine reproductive and respiratory syndrome negative serum; the protein mixed-encapsulated ELISA plate is coated with antigenic proteins: envelope protein GP5, membrane matrix protein M and nucleocapsid protein N. Compared with the existing mainstream technology that coats a single antigen, the triple-coated antigen detection antibody is more effective, which can effectively reduce the problem of detection failure or missed detection. In addition, a batch pre-processing device for serum samples was invented, which can mix serum in batches, and can use a multi-channel pipette to add samples at a time, which greatly improves efficiency and reduces errors.

The invention discloses a porcine epidemic diarrhea virus M protein affinity peptide and a screening method thereof. The amino acid sequence of the M protein affinity peptide is AGWYCTEVLCVQ or AYCTRHVCYLDN. The present invention uses phage display technology to obtain a short peptide that can specifically bind to PEDV and its recombinant protein M, and artificially synthesizes the short peptide, and analyzes its antiviral biological function. The results show that the present invention screens and synthesizes two PEDV M for the first time The affinity peptides of the protein can effectively inhibit the replication of PEDV, which provides a certain theoretical basis and experimental basis for the development of small molecule diagnostic and therapeutic preparations for PEDV in the future.

The invention belongs to the field of biotechnology, and in particular relates to an oncolytic virus vaccine and a drug for treating tumors in combination with immune checkpoint inhibitors. The invention provides a brand-new attenuated strain of oncolytic virus by performing site-directed mutation on the matrix protein M of vesicular stomatitis virus wild type virus. The attenuated strain can be used alone as a drug to treat tumors, and its safety and cure rate are superior to wild-type virus and other known attenuated strains. Based on the attenuated strain of oncolytic virus, the present invention also provides a vaccine applicable to tumor treatment by inserting NY-ESO-1 into the attenuated strain. The vaccine has a high cure rate and high biological safety. On the basis of the vaccine, the present invention also uses the vaccine in combination with immune checkpoint inhibitors to provide a drug that can efficiently treat multiple types of tumors; on the mouse lung cancer model, the cure rate can reach an astonishing 87.5% %, and has a better therapeutic effect on large tumors.

The purpose of the present invention is to develop a kit capable of detecting antigen or measuring its amount with high sensitivity without requiring an immobilization step and a washing step. The present invention provides a kit for detecting antigen or measuring its amount. The kit comprises a complex of a polypeptide including an antibody light chain variable region and a polypeptide including an antibody heavy chain variable region and a protein M fragment labeled with a fluorescent dye. The protein M fragment is a fragment having a binding ability to the complex.